1-15 of 15
Brian A. Van Tine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT191: First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data

Brian A. Van Tine, Eugene Ahn, Rebecca A. Redman, Minal A. Barve, William J. Edenfield, Julio Peguero, Victoria M. Villaflor, Drew W. Rasco, Steven F. Powell, Admasu T. Mamuye, Chris B. Moore, Joshua M. Pelham, Soratree Charoenthongtrakul, David R. Spigel
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT191.
https://doi.org/10.1158/1538-7445.AM2024-CT191
Published: 05 April 2024
View article titled, Abstract CT191: First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
Journal Articles

Abstract LB288: Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations

Lee D. Cranmer, Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian A. Van Tine, Rashmi Chugh, Erlinda M. Gordon, David J. Kwiatkowski, Jason L. Hornick, Heng Du, Li Ding, Anita N. Schmid, Willis H. Navarro, Loretta M. Itri, Mark A. Dickson
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB288.
https://doi.org/10.1158/1538-7445.AM2023-LB288
Published: 14 April 2023
View article titled, Abstract LB288: Biomarker analysis from AMPECT correlating response to <em>nab</em>-sirolimus with <em>TSC1</em> and <em>TSC2</em> inactivating alterations
Journal Articles

Abstract CT116: First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors

Benedito A. Carneiro, Maria Diab, Brian A. Van Tine, Anthony F. Shields, Albiruni Abdul Razak, John F. Hilton, Rafael Santana-Davila, Elhan Sanai, Jorge Zeron-Medina, Veronique Bragulat, Kath Lowery, Arthur Lambert, John Hood, Rakesh Kumar, Duncan Jodrell, Patricia LoRusso
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT116.
https://doi.org/10.1158/1538-7445.AM2023-CT116
Published: 14 April 2023
View article titled, Abstract CT116: First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors
Journal Articles

Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results

Meena Okera, Brian A. Van Tine, Joleen M. Hubbard, Minal Barve, Erika Hamilton, Monica M. Mita, Frances Valdes-Albini, Daniel Ahn, Admasu Mamuye, Joshua Pelham, Amy Yuet, Diana Yurewicz, Yanning Liu, Andres Machado Sandri, William J. Edenfield, Aki Morikawa, William Gradishar, Rajiv Kumar, Zev A. Wainberg
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT2-11-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT2-11-01
Published: 01 March 2023
View article titled, Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results
Journal Articles

Abstract P2-13-45: Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors

Brian A. Van Tine, Monica Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Angela Georgy, Joshua Pelham, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Zev A. Wainberg
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-45.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-45
Published: 15 February 2022
View article titled, Abstract P2-13-45: Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors
Journal Articles

Abstract CT130: Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors

Zev A. Wainberg, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Christine Burnett, Joshua Pelham, Eric T. Williams, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Brian A. Van Tine
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT130.
https://doi.org/10.1158/1538-7445.AM2021-CT130
Published: 01 July 2021
View article titled, Abstract CT130: Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors
Journal Articles

Abstract CT219: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer

Adam J. Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra D'Angelo, Brian H. Ladle, Jonathan Noujaim, Kai He, David Liebner, Adrian G. Sacher, John B.A.G. Haanen, Jeffrey Yachnin, Chao Huang, Brian A. Van Tine, Aisha Hasan, Thomas Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT219.
https://doi.org/10.1158/1538-7445.AM2021-CT219
Published: 01 July 2021
View article titled, Abstract CT219: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer
Journal Articles

Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin

Javier Martin-Broto, Antonio Lopez Pousa, Andrew Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean-Yves Blay, James S. Hu, Gerard J. Oakley, Hong Wang, Anna Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin Jones
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT009.
https://doi.org/10.1158/1538-7445.AM2019-CT009
Published: 01 July 2019
View article titled, Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin
Journal Articles

Abstract CT111: Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma

Bethany C. Prudner, Richa Rathore, Abigail Godec, Samuel F. Chang, Angela Hirbe, Brian A. Van Tine
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT111.
https://doi.org/10.1158/1538-7445.AM2019-CT111
Published: 01 July 2019
View article titled, Abstract CT111: Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma
Journal Articles

Abstract 616: Interferon gamma induced transformation of the cold tumor microenvironment in patients with NY-ESO-1 expressing sarcomas

Shihong Zhang, Sara Cooper, Bailey Donahue, Venu G. Pillarisetty, Robin L. Jones, Stanley R. Riddell, Brian A. Van Tine, Seth M. Pollack
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 616.
https://doi.org/10.1158/1538-7445.AM2018-616
Published: 01 July 2018
View article titled, Abstract 616: Interferon gamma induced transformation of the cold tumor microenvironment in patients with NY-ESO-1 expressing sarcomas
Journal Articles

Abstract CT145: A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS)

Victor Villalobos, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian A. Van Tine, Chukwuemeka Okereke, Wee Teck Ng, Damien M. Cronier
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT145.
https://doi.org/10.1158/1538-7445.AM2016-CT145
Published: 15 July 2016
View article titled, Abstract CT145: A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS)
Journal Articles

Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer

Matthew J. Ellis, Ding Li, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian A. Van Tine, Jeremy Hoog, Robert J. Crowder, Jacqueline E. Snider, Karla Ballman, Ken Chen, Daniel C. Koboldt, William S. Schierding, Joshua F. McMichael, Christopher A. Miller, Cyriac Kandoth, Charles Lu, Christopher C. Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura Esserman, Gary Unzeitig, Julie Margenthaler, G.V. Babiera, P. Kelly Marcom, J.M. Guenther, Marilyn Leitch, Kelly Hunt, John Olson, Yu Tao, Lucinda L. Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Malachi Griffith, Tammi L. Vickery, Sandra A. McDonald, Mark Watson, David J. Dooling, David Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, Richard K. Wilson, Elaine R. Mardis
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): LB-423.
https://doi.org/10.1158/1538-7445.AM2012-LB-423
Published: 15 April 2012
View article titled, Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer
Journal Articles

Abstract 5629: Arginine depravation therapy with arginine deiminase and autophagy inhibition is a novel therapeutic approach for the treatment of metastatic sarcomas that lack argininosuccinate synthetase expression

Dean Weich, Shunqiang Li, Tom Kitchens, Munir R. Tanas, Philip Boone, David Y. Chen, Douglas R. Adkins, John Bomalski, Brian P. Rubin, Brian A. Van Tine
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 5629.
https://doi.org/10.1158/1538-7445.AM2012-5629
Published: 15 April 2012
View article titled, Abstract 5629: Arginine depravation therapy with arginine deiminase and autophagy inhibition is a novel therapeutic approach for the treatment of metastatic sarcomas that lack argininosuccinate synthetase expression
Journal Articles

A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth

David Y. Chen, Yishan Lee, Brian A. Van Tine, Adam C. Searleman, Todd D. Westergard, Han Liu, Ho-Chou Tu, Shugaku Takeda, Yiyu Dong, David R. Piwnica-Worms, Kyoung J. Oh, Stanley J. Korsmeyer, Ann Hermone, Richard Gussio, Robert H. Shoemaker, Emily H.-Y. Cheng, James J.-D. Hsieh
Journal: Cancer Research
Cancer Res (2012) 72 (3): 736–746.
https://doi.org/10.1158/0008-5472.CAN-11-2584
Published: 31 January 2012
View article titled, A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth
Open the PDF for A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis

David Y. Chen, Han Liu, Shugaku Takeda, Ho-Chou Tu, Satoru Sasagawa, Brian A. Van Tine, Dongsi Lu, Emily H-Y. Cheng, James J-D. Hsieh
Journal: Cancer Research
Cancer Res (2010) 70 (13): 5358–5367.
https://doi.org/10.1158/0008-5472.CAN-10-0027
Published: 30 June 2010
View article titled, Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis
Open the PDF for Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis in another window
Includes: Supplementary data